266 related articles for article (PubMed ID: 25490969)
21. The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis.
Li H; Xie S; Liu M; Chen Z; Liu X; Wang L; Li D; Zhou Y
Int J Oncol; 2014 Jul; 45(1):197-208. PubMed ID: 24805774
[TBL] [Abstract][Full Text] [Related]
22. MicroRNAs in melanoma biology.
Kunz M
Adv Exp Med Biol; 2013; 774():103-20. PubMed ID: 23377970
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
Jönsson G; Busch C; Knappskog S; Geisler J; Miletic H; Ringnér M; Lillehaug JR; Borg A; Lønning PE
Clin Cancer Res; 2010 Jul; 16(13):3356-67. PubMed ID: 20460471
[TBL] [Abstract][Full Text] [Related]
24. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway.
Nosho K; Igarashi H; Nojima M; Ito M; Maruyama R; Yoshii S; Naito T; Sukawa Y; Mikami M; Sumioka W; Yamamoto E; Kurokawa S; Adachi Y; Takahashi H; Okuda H; Kusumi T; Hosokawa M; Fujita M; Hasegawa T; Okita K; Hirata K; Suzuki H; Yamamoto H; Shinomura Y
Carcinogenesis; 2014 Apr; 35(4):776-83. PubMed ID: 24242331
[TBL] [Abstract][Full Text] [Related]
25. Integrated analyses of microRNA and mRNA expression profiles in aggressive papillary thyroid carcinoma.
Yang Z; Yuan Z; Fan Y; Deng X; Zheng Q
Mol Med Rep; 2013 Nov; 8(5):1353-8. PubMed ID: 24064622
[TBL] [Abstract][Full Text] [Related]
26. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
[TBL] [Abstract][Full Text] [Related]
27. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
[TBL] [Abstract][Full Text] [Related]
28. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
Wang B; Li J; Sun M; Sun L; Zhang X
IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313
[TBL] [Abstract][Full Text] [Related]
29. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
30. Global microRNA profiling of metastatic conjunctival melanoma.
Mikkelsen LH; Andersen MK; Andreasen S; Larsen AC; Tan Q; Toft PB; Wadt K; Heegaard S
Melanoma Res; 2019 Oct; 29(5):465-473. PubMed ID: 30932942
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of BRAF mutations in localized cutaneous melanoma.
Nagore E; Requena C; Traves V; Guillen C; Hayward NK; Whiteman DC; Hacker E
J Am Acad Dermatol; 2014 May; 70(5):858-62.e1-2. PubMed ID: 24388723
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
[TBL] [Abstract][Full Text] [Related]
33. Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit.
Zhang Z; Zhang S; Ma P; Jing Y; Peng H; Gao WQ; Zhuang G
Carcinogenesis; 2015 Sep; 36(9):937-45. PubMed ID: 26071398
[TBL] [Abstract][Full Text] [Related]
34. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
Ruggiero CF; Fattore L; Terrenato I; Sperati F; Salvati V; Madonna G; Capone M; Valenti F; Di Martino S; Mandoj C; Liguoro D; Castaldo V; Cafaro G; Simeone E; Vanella V; Russillo M; Conti L; Cuda G; Giannarelli D; Ascierto PA; Mancini R; Ciliberto G
Theranostics; 2022; 12(17):7420-7430. PubMed ID: 36438490
[No Abstract] [Full Text] [Related]
35. MicroRNAs expression associated with aggressive clinicopathological features and poor prognosis in primary cutaneous melanomas.
Murria Estal R; de Unamuno Bustos B; Pérez Simó G; Simarro Farinos J; Torres Navarro I; Alegre de Miquel V; Ballester Sánchez R; Sabater Marco V; Llavador Ros M; Palanca Suela S; Botella Estrada R
Melanoma Res; 2021 Feb; 31(1):18-26. PubMed ID: 33234848
[TBL] [Abstract][Full Text] [Related]
36. Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information.
Jayawardana K; Schramm SJ; Haydu L; Thompson JF; Scolyer RA; Mann GJ; Müller S; Yang JY
Int J Cancer; 2015 Feb; 136(4):863-74. PubMed ID: 24975271
[TBL] [Abstract][Full Text] [Related]
37. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
Shiiyama R; Fukushima S; Jinnin M; Yamashita J; Miyashita A; Nakahara S; Kogi A; Aoi J; Masuguchi S; Inoue Y; Ihn H
Melanoma Res; 2013 Oct; 23(5):366-72. PubMed ID: 23863473
[TBL] [Abstract][Full Text] [Related]
38. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients.
Ono S; Oyama T; Lam S; Chong K; Foshag LJ; Hoon DS
Oncotarget; 2015 Mar; 6(9):7053-64. PubMed ID: 25749524
[TBL] [Abstract][Full Text] [Related]
39. MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab.
Wagenseller AG; Shada A; D'Auria KM; Murphy C; Sun D; Molhoek KR; Papin JA; Dutta A; Slingluff CL
J Transl Med; 2013 Sep; 11():218. PubMed ID: 24047116
[TBL] [Abstract][Full Text] [Related]
40. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma.
Mann GJ; Pupo GM; Campain AE; Carter CD; Schramm SJ; Pianova S; Gerega SK; De Silva C; Lai K; Wilmott JS; Synnott M; Hersey P; Kefford RF; Thompson JF; Yang YH; Scolyer RA
J Invest Dermatol; 2013 Feb; 133(2):509-17. PubMed ID: 22931913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
